CF PHARMTECH (02652) announced that the group has recently submitted a marketing authorization application for CF017 (Budesonide Suspension for Inhalation) to relevant drug regulatory authorities in Southeast Asia. CF017 was approved for marketing by the National Medical Products Administration of China in May 2021 and has since been commercially available domestically. Southeast Asia, with its large and growing population, increasing healthcare demands, and rising incidence of respiratory diseases, represents a market with significant potential for high-quality inhalation preparations. The company believes that submitting the marketing authorization application for CF017 in Southeast Asia marks a new step in the group's global strategy to expand its international commercial presence.